We report on a female patient who presented with severe intellectual disability and autistic behavior, dysmorphic features, orodental anomalies, and bilateral calcification of basal ganglia. Using a high-density oligonucleotide microarray, we have identified a de novo duplication of 11q13.1q22.1 involving the dosage sensitive genes FGF3 and FGF4, genes related to autosomal dominant disorders KMT5B, GAL, SPTBN2, and LRP5, susceptibility loci SCZD2, SLEH1, and SHANK2, mitochondrial genes NDUFV1, NDUFS8, and TMEM126B, and many loss of function genes, including PHOX2A, CLPB, MED17, B3GNT1, LIPT2, and CLPB. However, the duplication did not involve Ribonuclease H2, subunit C (RNASEH2C) which is considered to be located in the critical region for Aicardi-Goutières syndrome. In combination with the duplication at 11q13.1, a 1.849-Mb heterozygous duplication at 4q35.2 was also identified. Although this duplicated region does not contain causative genes related to brain calcification, the duplication at 4q35 was reported previously in a patient with basal ganglia calcification, coats' like retinopathy, and glomerulosclerosis. Our patient's presentation and genomic findings indicate that duplication of 4q35.2 could be a novel genetic cause of calcification of basal ganglia. Our report also underscores the clinical significance of rearrangements in 11q13.1q22.1 in the pathogenesis of basal ganglia calcification.

1.
Agostini A, Marchetti D, Izzi C, Cocco I, Pinelli L, et al: Expanding the phenotype of MED17 mutations: description of two new cases and review of the literature. Am J Med Genet 177 B:687-690 (2018).
2.
Burnside DR, Lose EJ, Domínguez MG, Sánchez-Corona J, Rivera H, et al: Molecular cytogenetic characterization of two cases with constitutional distal 11q duplication/triplication. Am J Med Genet 149A:1516-1522 (2009).
3.
Celle L, Lee L, Rintoul N, Savani RC, Long W, et al: Duplication of chromosome region 4q283-qter in monozygotic twins with discordant phenotypes. Am J Med Genet 94:125-140 (2000).
4.
Crow YJ: Type I interferonopathies: Mendelian type I interferon up-regulation. Curr Opin Immunol 32:7-12 (2015).
5.
de Die-Smulders CE, Engelen JJ: 11Q duplication in a patient with Pitt-Rogers-Danks phenotype. Am J Med Genet 66:116-117(1996).
6.
Egritas O, Cavdarli B, Dalgic B, Ergun MA, Percin, et al: Duplication 4q associated with chronic cholestatic changes in liver biopsy. Eur J Med Genet 53:411-414 (2010).
7.
Gregory-Evans CY, Moosajee M, Hodges MD, Mackay DS, Game L, et al: SNP genome scanning localizes oto-dental syndrome to chromosome 11q13 and microdeletions at this locus implicate FGF3 in dental and inner-ear disease and FADD in ocular coloboma. Hum Mol Genet 16:2482-2493 (2007).
8.
Greig F, Rosenfeld W, Verma RS, Babu KA, David K: Duplication 11 (q22-qter) in an infant. A case report with review. Ann Genet 28:185-188 (1985).
9.
Grillo L, Greco D, Pettinato R, Avola E, Potenza N, et al: Increased FGF3 and FGF4 gene dosage is a risk factor for craniosynostosis. Gene 534:435-439 (2014).
10.
Jehee FS, Bertola DR, Yelavarthi KK, Krepischi-Santos ACV, Kim C, et al: An 11q11-q133 duplication, including FGF3 and FGF4 genes, in a patient with syndromic multiple craniosynostosis. Am J Med Genet 143A:1912-1918 (2007).
11.
Kayhan G, Cavdarli B, Yirmibes Karaoguz M, Percin EF, Oztürk Kaymak A, et al: Molecular karyotyping of an isolated partial trisomy 11q patient with additional findings. Gene 524:355-360 (2013).
12.
Kettunen P, Karavanova I, Thesleff I: Responsiveness of developing dental tissues to fibroblast growth factors: expression of splicing alternatives of FGFR1, -2, -3, and of FGFR4; and stimulation of cell proliferation by FGF-2, -4, -8, and -9. Dev Genet 22:374-385 (1998).
13.
Legius E, Wlodarska I, Selleri L, Evans GA, Wu R, et al: De novo 46,XX, dir dup (11)(q133.3→q14.2) in a patient with mental retardation, congenital cardiopathy and thrombopenia. Clin Genet 49:206-210 (1996).
14.
Lin S, Kirk EPE, McKenzie F, Francis C, Shalhoub C, Turner AM: De novo interstitial duplication 4(q281q35) associated with choanal atresia. J Paediatr Child Health 40:401-403 (2004).
15.
Livingston JH, Stivaros S, Van Der Knaap MS, Crow YJ: Recognizable phenotypes associated with intracranial calcification. Dev Med Child Neurol 55:46-57 (2013).
16.
Mikelsaar, RV, Lurie IW, Ilus TE: Pure' partial trisomy 4q25-qter owing to a de novo 4;22 translocation. J Med Genet 33:344-345 (1996).
17.
Nakayama T, Sakakihara Y, Hanaoka S, Akagi K, Kamoshita S: Calcification of basal ganglia in a patient with partial trisomy 5q and partial monosomy 18q. Acta Paediatr Jpn 35:340-344 (1993).
18.
Priest FJ, Clarkson M, Nevin NC, Edgar D, Calver GJ: Duplication of 4q syndrome resulting from a familial 4;14 translocation. J Med Genet 28:573 (1991).
19.
Reynolds BC, Lemmers RJLF, Tolmie J, Howatson AG, Hughes DA: Focal segmental glomerulosclerosis, Coats'-like retinopathy, sensorineural deafness and chromosome 4 duplication: a new association. Pediatr Nephrol 25:1551-1554 (2010).
20.
Rinaldi R, De Bernardo C, Assumma M, Grammatico B, Buffone E, et al: Cytogenetic and molecular characterization of a de novo 4q24qter duplication and correlation to the associated phenotype. Am J Med Genet 118A:122-126 (2003).
21.
Taylor KM, Francke U, Brown MG, George DL, Kaufhold M, Opitz JM: Inverted tandem (“mirror”) duplications in human chromosomes: -nv dup 8p, 4q, 22q. Am J Med Genet 1:3-19 (1977).
22.
Tekin M, Hişmi BÖ, Fitoz S, Özdağ H, Cengiz FB, et al: Homozygous mutations in fibroblast growth factor 3 are associated with a new form of syndromic deafness characterized by inner ear agenesis, microtia, and microdontia. Am J Hum Genet 80:338-344 (2007).
23.
Thapa M, Asamoah A, Gowans GC, Platky KC, Barch MJ, et al: Molecular characterization of distal 4q duplication in two patients using oligonucleotide array-based comparative genomic hybridization (oaCGH) analysis. Am J Med Genet Part A 164:1069-1074 (2014).
24.
Xiao B, Xu H, Ye H, Hu Q, Chen Y, Qiu W: De novo 11q13.4q14.3 tetrasomy with uniparental isodisomy for 11q14.3qter. Am J Med Genet A 167A:2327-2333 (2015).
25.
Yelavarthi KK, Zunich J: Familial interstitial duplication of 11q; partial trisomy (11)(q13.5q21). Am J Med Genet 126A:423-426 (2004).
26.
Yoshikawa, H, Abe T: Hypoparathyroidism and facial dysmorphism as main symptoms of 22q11 deletion syndrome. Brain Dev 25:211-214 (2003).
27.
Zarate YA, Kogan JM, Schorry EK, Smolarek TA, Hopkin RJ: A new case of de novo 11q duplication in a patient with normal development and intelligence and review of the literature. Am J Med Genet 143A:265-270 (2007).
28.
Zhao H, Rop AF, Saal HM, Blough-Pfau RI, Hopkin RJ: Upper airway malformation associated with partial trisomy 11q. Am J Med Genet 120A:331-337 (2003).
29.
Ziebart T, Draenert FG, Galetzka D, Babaryka G, Schmidseder R, et al: The original family revisited after 37 years: odontoma-dysphagia syndrome is most likely caused by a microduplication of chromosome 11q133, including the FGF3 and FGF4 genes. Clin Oral Investig 17:123-130 (2013).
30.
Zimberg-Bossira A, Smolkin T, Gildish A, Moustafa-Hawash N, Blazer S, et al: ‘Pure' partial trisomy 11q (11q23.1-11qter): Expanding the phenotype. Clin Dysmorphol 20:225-228 (2011).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.